|
1
|
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
|
Ann Rheum Dis
|
2004
|
2.18
|
|
2
|
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations.
|
Ann Rheum Dis
|
2004
|
2.15
|
|
3
|
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
|
Ann Rheum Dis
|
2000
|
1.79
|
|
4
|
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.
|
Arthritis Rheum
|
2001
|
1.70
|
|
5
|
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity.
|
Ann Rheum Dis
|
2000
|
1.47
|
|
6
|
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms.
|
Lancet
|
2000
|
1.42
|
|
7
|
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis.
|
Ann Rheum Dis
|
2005
|
1.31
|
|
8
|
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
|
Ann Rheum Dis
|
2003
|
1.31
|
|
9
|
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha.
|
Ann Rheum Dis
|
2001
|
1.13
|
|
10
|
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.
|
Lupus
|
2005
|
1.05
|
|
11
|
Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment.
|
Ann Rheum Dis
|
2005
|
0.96
|
|
12
|
Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis.
|
Ann Rheum Dis
|
2006
|
0.87
|
|
13
|
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
|
Br J Cancer
|
1996
|
0.82
|
|
14
|
Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo.
|
Ann Rheum Dis
|
2007
|
0.81
|
|
15
|
Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model.
|
Cancer Gene Ther
|
2008
|
0.80
|
|
16
|
Ex vivo pulsatile perfusion of human saphenous veins induces intimal hyperplasia and increased levels of the plasminogen activator inhibitor 1.
|
Eur Surg Res
|
2010
|
0.80
|
|
17
|
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
|
J Gastroenterol Hepatol
|
1994
|
0.78
|
|
18
|
Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.
|
Ann Rheum Dis
|
2001
|
0.78
|
|
19
|
Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis.
|
Ann Rheum Dis
|
2002
|
0.75
|
|
20
|
Tenosynovitis with acute onset: unexpected giant cell tumour of the tendon sheath.
|
Ann Rheum Dis
|
2002
|
0.75
|
|
21
|
Characteristic marco- and microscopic aspect of the synovial membrane in crystal induced arthritis.
|
J Rheumatol
|
2001
|
0.75
|